Targeted Deep Sequencing Method Detects Rare Mutations in Circulating Tumor DNA | GenomeWeb

Researchers in the UK have developed a targeted sequencing approach to detect mutations in circulating tumor DNA that they believe could eventually be developed as a clinical assay for early cancer diagnosis or to monitor disease progression and treatment response.

Their strategy, tagged-amplicon deep sequencing, or TAm-Seq, is a two-step amplification process that combines the Fluidigm Access Array with Illumina sequencing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.